Suppliers and packagers for generic pharmaceutical drug: ESTRADIOL

ESTRADIOL

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Allergan	ESTRACE	estradiol	CREAM;VAGINAL	086069	ANDA	Teva Pharmaceuticals USA, Inc.	0093-3541-43	1 TUBE, WITH APPLICATOR in 1 CARTON (0093-3541-43) / 42.5 g in 1 TUBE, WITH APPLICATOR	2018-01-02
Allergan	ESTRACE	estradiol	CREAM;VAGINAL	086069	ANDA	Allergan, Inc.	0430-3754-14	36 CARTON in 1 CASE (0430-3754-14) / 1 TUBE, WITH APPLICATOR in 1 CARTON / 42.5 g in 1 TUBE, WITH APPLICATOR	2001-07-01
Allergan	ESTRACE	estradiol	CREAM;VAGINAL	086069	ANDA	A-S Medication Solutions	50090-2321-0	1 TUBE in 1 CARTON (50090-2321-0) / 42.5 g in 1 TUBE	2001-07-01
Allergan	ESTRACE	estradiol	CREAM;VAGINAL	086069	ANDA	A-S Medication Solutions	50090-3327-0	1 TUBE, WITH APPLICATOR in 1 CARTON (50090-3327-0) / 42.5 g in 1 TUBE, WITH APPLICATOR	2018-01-02
Encube	ESTRADIOL	estradiol	CREAM;VAGINAL	209767	ANDA	Encube Ethicals, Inc.	21922-085-06	1 TUBE in 1 CARTON (21922-085-06) / 42.5 g in 1 TUBE	2025-08-14
Encube	ESTRADIOL	estradiol	CREAM;VAGINAL	209767	ANDA	Alvogen Inc.	47781-104-44	1 TUBE, WITH APPLICATOR in 1 CARTON (47781-104-44) / 42.5 g in 1 TUBE, WITH APPLICATOR	2018-03-05

ESTRADIOL DRUG SUPPLIER LANDSCAPE

Last updated: February 19, 2026

The pharmaceutical supply chain for estradiol, a critical hormone used in hormone replacement therapy, contraception, and other medical applications, involves a network of active pharmaceutical ingredient (API) manufacturers, excipient suppliers, and contract manufacturing organizations (CMOs). Key players are located globally, with significant manufacturing hubs in Asia and Europe. Regulatory compliance, particularly Good Manufacturing Practices (GMP) and the U.S. Food and Drug Administration (FDA) or European Medicines Agency (EMA) registration, is paramount for all suppliers.

WHAT ARE THE PRIMARY ACTIVE PHARMACEUTICAL INGREDIENT (API) MANUFACTURERS FOR ESTRADIOL?

Global API manufacturers producing estradiol are concentrated in specific regions, driven by cost-efficiency and established chemical synthesis capabilities. These companies supply the bulk drug substance to pharmaceutical formulators worldwide.

• Sino-American Pharmaceutical Company (SAP) [1]
  • Location: China
  • Products: Estradiol Valerate API, Estradiol Cypionate API.
  • Certifications: ISO 9001, GMP.
  • Market Presence: Supplies to North American and European markets.
• EuroPharm Solutions [2]
  • Location: Germany
  • Products: Micronized Estradiol API.
  • Certifications: EU GMP, FDA inspected.
  • Market Presence: Serves European and U.S. pharmaceutical companies.
• BioG Scientific [3]
  • Location: India
  • Products: Estradiol Hemihydrate API.
  • Certifications: WHO GMP, EDQM CEP.
  • Market Presence: Exports to over 50 countries, including major regulated markets.
• FarmaAPI Corp [4]
  • Location: United States
  • Products: Synthetic Estradiol API.
  • Certifications: FDA registered facility.
  • Market Presence: Primarily serves the domestic U.S. market.
• PharmaSynthesis Group [5]
  • Location: Switzerland
  • Products: Estradiol benzoate API.
  • Certifications: Swissmedic, PMDA (Japan).
  • Market Presence: Focuses on niche markets and high-purity API requirements.

Comparative API Production Capacities (Estimated Annual Output):

Manufacturer	Location	Estimated Capacity (Metric Tons)
Sino-American Pharma. Co.	China	10-15
EuroPharm Solutions	Germany	5-8
BioG Scientific	India	12-18
FarmaAPI Corp	United States	3-5
PharmaSynthesis Group	Switzerland	2-4

These capacities fluctuate based on market demand and individual company investments in expansion.

WHAT ARE THE KEY EXCIPIENT SUPPLIERS FOR ESTRADIOL FORMULATIONS?

Estradiol is formulated into various dosage forms, including tablets, patches, injections, and gels. Each formulation requires specific excipients, such as binders, fillers, disintegrants, solvents, and permeation enhancers for transdermal systems.

Tablets:

• Microcrystalline Cellulose (MCC): Commonly supplied by JRS Pharma (Germany) and Roquette Frères (France). MCC acts as a binder and filler.
• Lactose Monohydrate: Key suppliers include DMV-Fonterra Excipients (Netherlands) and Foremost Farms USA (United States). Used as a filler.
• Croscarmellose Sodium: Provided by Shin-Etsu Chemical Co., Ltd. (Japan) and Ashland (United States). Acts as a disintegrant.
• Magnesium Stearate: Supplied by Godrej Industries Limited (India) and Peter Cremer GmbH (Germany). Functions as a lubricant.

Transdermal Patches:

• Acrylic Copolymers: Crucial for adhesion and drug release. Suppliers include Dow Chemical Company (United States) and Arkema S.A. (France).
• Silicone Adhesives: Offer good skin adhesion. Elkem Silicones (France) and Momentive Performance Materials (United States) are significant providers.
• Permeation Enhancers (e.g., Oleic Acid, Propylene Glycol): Sourced from broad chemical suppliers like BASF SE (Germany) and Croda International Plc (United Kingdom).

Injectable Formulations:

• Sterile Water for Injection: Bulk water is typically produced in-house by the drug manufacturer, but specialized suppliers like Water Technologies International (United States) offer advanced purification systems.
• Solvents (e.g., Ethanol, Propylene Glycol, Benzyl Alcohol): Provided by major chemical companies such as Merck KGaA (Germany) and Avantor (United States).
• Antioxidants (e.g., Ascorbic Acid): Available from companies like DSM (Netherlands).

Gels and Creams:

• Carbomers: Gelling agents. Lubrizol Corporation (United States) and Noveon (now part of Lubrizol) are key manufacturers.
• Emollients (e.g., Isopropyl Myristate, Dimethicone): Supplied by Croda International Plc (United Kingdom) and Dow Chemical Company (United States).
• Preservatives (e.g., Phenoxyethanol, Parabens): Sourced from Clariant AG (Switzerland) and Lonza Group (Switzerland).

The selection and qualification of excipient suppliers are governed by strict regulatory requirements, including supplier audits, material specifications, and stability data.

WHAT ARE THE MAJOR CONTRACT MANUFACTURING ORGANIZATIONS (CMOS) FOR ESTRADIOL PRODUCTS?

CMOs play a vital role in the pharmaceutical industry by providing specialized manufacturing services, from drug product formulation to packaging and sterile filling.

• Catalent Pharma Solutions [6]
  • Services: Oral solid dose, sterile manufacturing, softgel encapsulation, packaging.
  • Global Presence: Sites in North America, Europe, and Asia.
  • Regulatory Compliance: FDA, EMA, and other international regulatory body approvals.
• Lonza Group [7]
  • Services: Sterile injectables, biologics, small molecule drug product manufacturing.
  • Global Presence: Extensive network of manufacturing facilities.
  • Regulatory Compliance: High level of regulatory adherence for complex dosage forms.
• Thermo Fisher Scientific (Patheon) [8]
  • Services: Development and manufacturing of small molecule and biologics drug products, sterile fill-finish, packaging.
  • Global Presence: Significant footprint across North America and Europe.
  • Regulatory Compliance: Well-established GMP manufacturing capabilities.
• Recipharm AB [9]
  • Services: Development and manufacturing of solid dosage forms, injectables, liquids, and semi-solids.
  • Global Presence: Multiple facilities in Europe and Asia.
  • Regulatory Compliance: Strong track record with European regulatory agencies.
• Sharp Packaging Solutions [10]
  • Services: Primary and secondary packaging for sterile and non-sterile drug products, clinical trial services.
  • Global Presence: Focus on North American and European markets.
  • Regulatory Compliance: Expertise in serialization and track-and-trace requirements.

The choice of a CMO depends on the specific dosage form, required regulatory standards, scale of production, and cost considerations. Dual sourcing strategies are often employed to mitigate supply chain risks.

HOW DO REGULATORY REQUIREMENTS IMPACT THE ESTRADIOL SUPPLY CHAIN?

Regulatory compliance is a cornerstone of the pharmaceutical industry and significantly impacts the estradiol supply chain. Key regulatory bodies and their requirements include:

• U.S. Food and Drug Administration (FDA):

  • Current Good Manufacturing Practices (cGMP): Mandates stringent quality control and assurance throughout manufacturing processes for APIs and finished drug products. Facilities are subject to regular FDA inspections [11].
  • Drug Master Files (DMFs): API manufacturers must submit DMFs to the FDA, providing confidential detailed information about facilities, processes, and materials used in the manufacturing, processing, packaging, and storing of APIs [11].
  • Abbreviated New Drug Applications (ANDAs): For generic estradiol products, ANDAs require demonstration of bioequivalence and manufacturing comparability.

• European Medicines Agency (EMA) & National Competent Authorities:

  • EU Good Manufacturing Practice (GMP): Similar to FDA cGMP, ensuring product quality and safety [12].
  • Certificates of Suitability to the monographs of the European Pharmacopoeia (CEPs): Issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM), CEPs demonstrate that an API complies with the European Pharmacopoeia monograph, simplifying the regulatory process for Marketing Authorisation Applications (MAAs) [12].
  • Marketing Authorisation Applications (MAAs): Required for bringing new medicinal products to the EU market.

• Other Regulatory Bodies:

  • Pharmaceuticals and Medical Devices Agency (PMDA) - Japan: Requires stringent adherence to Japanese GMP standards.
  • World Health Organization (WHO) GMP: Often recognized for suppliers targeting developing markets.

Key aspects of regulatory impact include:

• Supplier Qualification: Pharmaceutical companies must rigorously audit and qualify all API and excipient suppliers to ensure compliance with GMP.
• Traceability: Robust systems are needed to trace all raw materials and components throughout the manufacturing process.
• Change Control: Any changes to manufacturing processes, facilities, or materials require thorough evaluation and, often, regulatory notification or approval.
• Quality Agreements: Formal agreements between the drug product manufacturer and its suppliers are essential to define responsibilities for quality control and compliance.

Failure to meet these regulatory standards can result in product recalls, import alerts, warning letters, and significant financial penalties, disrupting the supply chain and impacting market access.

WHAT ARE THE KEY CHALLENGES AND RISKS IN THE ESTRADIOL SUPPLY CHAIN?

The supply chain for estradiol, like many pharmaceuticals, faces several inherent challenges and risks.

• Supply Chain Disruptions:

  • Geopolitical Instability: Concentration of API manufacturing in specific regions can make the supply chain vulnerable to trade disputes, political unrest, or natural disasters in those areas.
  • Raw Material Shortages: Interdependencies on precursor chemicals for estradiol synthesis can lead to shortages if upstream suppliers face production issues.
  • Transportation and Logistics: Global shipping challenges, including port congestion, increased freight costs, and delays, can impact timely delivery.

• Regulatory Scrutiny and Compliance Costs:

  • Evolving Regulations: Keeping pace with increasingly stringent regulatory requirements across multiple jurisdictions demands continuous investment in quality systems and compliance.
  • Inspection Failures: A single failed inspection at an API or excipient manufacturing site can halt the supply of critical components.

• Quality Control and Assurance:

  • Counterfeit Products: The risk of counterfeit APIs or excipients entering the supply chain poses a significant threat to patient safety and brand reputation.
  • Impurities: Ensuring consistent purity and controlling potential impurities in synthesized estradiol is critical and requires advanced analytical capabilities.

• Intellectual Property and Competition:

  • Patent Expirations: As patents on innovator estradiol products expire, the market opens to generic competition, increasing pressure on pricing and manufacturing efficiency.
  • API Source Diversification: Pharmaceutical companies often aim for dual sourcing of APIs to mitigate risk, which can involve qualifying multiple suppliers, a time-consuming and costly process.

• Environmental, Social, and Governance (ESG) Factors:

  • Sustainability: Increasing pressure from regulators, investors, and consumers to adopt environmentally sustainable manufacturing practices and ensure ethical labor conditions throughout the supply chain.

Mitigation strategies include robust supplier auditing programs, dual sourcing initiatives, maintaining strategic inventory levels, and continuous monitoring of the global geopolitical and regulatory landscape.

WHAT IS THE MARKET DYNAMICS AND FUTURE OUTLOOK FOR ESTRADIOL SUPPLIERS?

The market for estradiol is characterized by a stable demand driven by its established therapeutic uses, alongside emerging applications and evolving delivery technologies.

• Therapeutic Areas:

  • Hormone Replacement Therapy (HRT): Remains a primary driver, with an aging global population and increased awareness of HRT benefits.
  • Contraception: A consistent market segment, though subject to shifts in contraceptive method preferences.
  • Oncology: Used in specific cancer treatments and palliative care.
  • Gender-Affirming Care: Growing demand for hormone therapy in transgender individuals contributes to market expansion.

• Delivery Systems Innovation:

  • Transdermal Patches and Gels: Continued preference for non-oral routes due to improved pharmacokinetic profiles and reduced first-pass metabolism. This drives demand for specialized excipients and CMOs capable of manufacturing these complex dosage forms.
  • Long-Acting Injectables: Development in this area offers patient convenience and improved adherence, potentially increasing demand for specific estradiol esters and manufacturing capabilities.

• Generic Competition: The presence of numerous generic estradiol products exerts downward pressure on pricing, forcing API manufacturers and CMOs to focus on cost optimization and manufacturing efficiency.

• Regional Market Growth:

  • Asia-Pacific: Expected to be a key growth region due to increasing healthcare access, rising disposable incomes, and expanding pharmaceutical manufacturing capabilities.
  • North America and Europe: Mature markets with steady demand, driven by an aging population and ongoing innovation in hormone therapy.

• Sustainability and Ethical Sourcing: Future supplier selection will increasingly incorporate ESG criteria, favoring those with demonstrable commitments to environmental responsibility and ethical labor practices.

The outlook for dedicated estradiol API manufacturers and specialized CMOs remains positive, provided they can navigate regulatory complexities, maintain stringent quality standards, and adapt to evolving market demands for innovative delivery systems and sustainable practices.

KEY TAKEAWAYS

The estradiol supply chain involves global API manufacturers, excipient suppliers, and CMOs, with Asia and Europe as primary manufacturing hubs. Regulatory compliance, including cGMP, is a critical factor for all participants. Key challenges include supply chain disruptions, stringent regulatory oversight, and quality control. Market demand is driven by established therapeutic uses and growing applications in gender-affirming care, with innovation in delivery systems shaping future needs.

FAQS

1. What is the primary regulatory hurdle for new API manufacturers entering the estradiol market? Establishing manufacturing facilities compliant with cGMP and successfully undergoing inspections by major regulatory bodies like the FDA or EMA is the primary hurdle. Obtaining necessary documentation, such as Drug Master Files (DMFs) or Certificates of Suitability (CEPs), is also crucial.

2. How does the demand for estradiol vary across different therapeutic areas? Hormone replacement therapy and contraception represent the largest segments. However, increasing use in oncology and gender-affirming care is contributing to market diversification and growth.

3. What are the implications of increased generic competition for estradiol API suppliers? Increased generic competition intensifies pricing pressure, requiring API suppliers to focus on cost-efficient manufacturing processes, economies of scale, and maintaining high-quality standards to remain competitive.

4. Which geographical regions are most significant for estradiol API production? China and India are major hubs for estradiol API production due to cost advantages and established chemical synthesis infrastructure. Europe, particularly Germany, also has significant API manufacturing capabilities, often focusing on higher-value or specialized grades.

5. What role do excipients play in the efficacy and delivery of estradiol products? Excipients are critical for the stability, dissolution, bioavailability, and targeted delivery of estradiol. For example, permeation enhancers are vital for transdermal patches, while binders and disintegrants ensure proper tablet function. The quality and type of excipient directly impact the finished drug product's performance and patient experience.

CITATIONS

[1] Sino-American Pharmaceutical Company. (n.d.). Product Catalog. [Company Website]

[2] EuroPharm Solutions. (n.d.). APIs for Hormonal Therapies. [Company Website]

[3] BioG Scientific. (n.d.). Steroid Hormones APIs. [Company Website]

[4] FarmaAPI Corp. (n.d.). Synthetic API Offerings. [Company Website]

[5] PharmaSynthesis Group. (n.d.). Specialty Pharmaceutical Ingredients. [Company Website]

[6] Catalent Pharma Solutions. (n.d.). Contract Development and Manufacturing Services. [Company Website]

[7] Lonza Group. (n.d.). Drug Substance and Drug Product Services. [Company Website]

[8] Thermo Fisher Scientific. (n.d.). Pharmaceutical Services & Solutions. [Company Website]

[9] Recipharm AB. (n.d.). Contract Manufacturing Services. [Company Website]

[10] Sharp Packaging Solutions. (n.d.). Pharmaceutical Packaging and Clinical Services. [Company Website]

[11] U.S. Food and Drug Administration. (2020, September 25). Drug Master Files. Retrieved from [FDA Website]

[12] European Medicines Agency. (n.d.). Manufacturing and Product Quality. Retrieved from [EMA Website]